



Supplementary Fig. S1

A




B




Supplementary Fig. S1 Clinical symptom and diagnosis of leptomenigeal metastasis. (A) Transverse T2-weighted Fast Spin Echo (FSE) sequence MRI image of Type D (arrows, mild hydrocephalus only) patient in our cohort. (B) Diagnostic process of leptomenigeal metastasis. Abbreviations: LM, leptomenigeal metastasis; MRI, magnetic resonance imaging; CSF, cerebrospinal fluid (analysis).

Supplementary Fig. S2



Supplementary Fig. S2 Clinical management of leptomeningeal metastasis. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status.

Supplementary Fig. S3



Supplementary Fig. S3 Survival prognosis analysis of leptomeningeal metastasis. (A) Distribution of ECOG PS status across different treatment groups. *P* value calculated by Fisher's exact test. (B - C) Forest plots showing the HR and 95% CI for combination treatments, based on multivariate Cox hazard analysis. (B) systemic chemotherapy with intrathecal chemotherapy, and (C) systemic chemotherapy with radiotherapy. *P* value calculated by log-rank test. Abbreviations: LM, leptomeningeal metastasis; BM, brain parenchymal metastasis; ECOG PS, Eastern Cooperative Oncology Group Performance Status; CI, confidence intervals.